These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10894354)

  • 1. Evolving strategies to address adverse transplant outcomes associated with T cell depletion.
    Drobyski WR
    J Hematother Stem Cell Res; 2000 Jun; 9(3):327-37. PubMed ID: 10894354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
    Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical bone marrow transplantation without T-cell depletion.
    Chang YJ; Huang XJ
    Semin Oncol; 2012 Dec; 39(6):653-63. PubMed ID: 23206842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.
    Lynch BA; Vasef MA; Comito M; Gilman AL; Lee N; Ritchie J; Rumelhart S; Holida M; Goldman F
    Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.
    Drobyski WR; Gendelman M
    Leuk Lymphoma; 2002 Oct; 43(10):2011-6. PubMed ID: 12481900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
    Sykes M; Sharabi Y; Sachs DH
    Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
    Sykes M; Bukhari Z; Sachs DH
    Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved immune function with donor B-cell infusion after semi-allogeneic bone marrow transplantation in mice.
    Samuel S; Azar Y; Corchia N; Or R
    Arch Med Res; 2008 Jan; 39(1):61-8. PubMed ID: 18067997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
    Soiffer RJ; Ritz J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.